Skip to main content

*April 2025*

In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Christine Lovly discuss the significant lung cancer findings presented at the American Association for Cancer Research (AACR) 2025 Annual Meeting.  They discuss the results from the Beamion LUNG-1 trial, a phase 1a/1b dose escalation trial with dose confirmation and expansion, which showed that zongertinib elicited durable responses in patients with advanced, previously treated, unresectable or metastatic non-small cell lung cancer (NSCLC) that harbored a HER2 mutation, while sparing EGFR, limiting associated toxicities. Listen here.